Personalize Medicine. Save Lives. close

The New Gold Standard in Epigenetic Diagnostic Tests
Leading the way in DNA Methylation Diagnostic and Research Solutions

  • Making more of specific proteins helps cancer cells survive under conditions which would kill normal cells. All these cells are being starved. The large cells have been genetically modified to over-express SMAC/DIABLO (green), one protein involved in apoptosis. The normal cells are stressed and form red stress granules. Understanding how cancer cells subvert the death pathway may lead to new ways to treat cancer. Immunofluorescent photomicrograph. --- Image by © Nancy Kedersha/Science Faction/Corbis

Research Products & Services

RiboMed provides a variety of versatile bisulfite-free research tools and services for the study of CpG methlyation in DNA.

•  MethylMeter®: Quantitative DNA Methylation Detection

•  MethylMagnet®: Ultra Sensitive Methylated DNA isolation

•  CAP: Pioneering  ”Coupled Abscription PCR ” DNA Methylation Detection

read more

Clinical Diagnostics

RiboMed’s proprietary Abscription®-based DNA methylation diagnostic tests are leading the way in epigenetic and cancer diagnostics.

• Proprietary bisulfite free DNA Methylation Detection Clinical Diagnostic Assay Platform

• Theranostic Ovarian Cancer Assay

read more

Latest News

RiboMed presents new brain cancer stratification test at Molecular Medicine Tri Conference.

RiboMed and NuvOx Pharma to Collaborate on Brain Cancer Drug and Companion Diagnostic Test

RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response

RiboMed Receives Three Additional Patents for Disease Diagnostics Methods

© Copyright 2012. RiboMed Biotechnologies Inc. All rights reserved. - Ribomed -